Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers - PubMed (original) (raw)
Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers
P Duchêne-Marullaz et al. J Cardiovasc Pharmacol. 1983 May-Jun.
Abstract
We studied the effects of bepridil, a new antianginal agent, on the ambulatory electrocardiogram in seven human volunteers. The drug was administered in three sequential periods of 12 days separated by 24 days without treatment. Heart rate was not significantly altered at 200 mg/day, but fell from day 3 at 300 mg/day and from day 1 at 600 mg/day. Average fall in heart rate was approximately 8% at 300 mg/day and 11% at 600 mg/day (day 7). At 200 mg/day the peak plasma level was reached after 11 days of treatment (0.28 +/- 0.4 microgram/ml). At 300 mg/day, a plateau was reached on day 7 (0.44 +/- 0.04 micrograms/ml) and at 600 mg/day from day 8 (0.97 +/- 14 micrograms/ml). We found a highly significant relationship between blood concentration of bepridil and mean RR interval lengths over 24 h. The QTc interval was lengthened at all doses, but there was no significant correlation between plasma level and increase in QTc interval length.
Similar articles
- [Effect of bepridil on the heart rate of the healthy subject. Correlation with plasma levels].
Kantelip JP, Duchène-Marullaz P, Trolèse JF, Pognat JF. Kantelip JP, et al. Arch Mal Coeur Vaiss. 1983 Feb;76(2):221-6. Arch Mal Coeur Vaiss. 1983. PMID: 6407430 French. - [Anti-angina effect of the calcium antagonist bepridil in stable angina pectoris].
Schneider W, Mehlhorn C, Kaltenbach M, Bussmann WD. Schneider W, et al. Z Kardiol. 1985 Jun;74(6):341-7. Z Kardiol. 1985. PMID: 3895761 Clinical Trial. German. - Combination propranolol and bepridil therapy in stable angina pectoris.
Frishman WH, Charlap S, Farnham DJ, Sawin HS, Michelson EL, Crawford MH, DiBianco R, Kostis JB, Zellner SR, Michie DD, et al. Frishman WH, et al. Am J Cardiol. 1985 Mar 15;55(7):43C-49C. doi: 10.1016/0002-9149(85)90805-7. Am J Cardiol. 1985. PMID: 3883741 Clinical Trial. - Bepridil: a new long-acting calcium channel blocking agent.
Zeller FP, Spinler SA. Zeller FP, et al. Drug Intell Clin Pharm. 1987 Jun;21(6):487-92. doi: 10.1177/106002808702100601. Drug Intell Clin Pharm. 1987. PMID: 3301244 Review. - Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties.
Alpert JS, Coumel P, Greeff K, Krikler DM, Remme WJ, Schönbaum E, Verduyn CW. Alpert JS, et al. Pharmatherapeutica. 1985;4(4):195-222. Pharmatherapeutica. 1985. PMID: 2414784 Review.
Cited by
- Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.
Berger F, Borchard U, Hafner D. Berger F, et al. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jun;339(6):638-46. doi: 10.1007/BF00168656. Naunyn Schmiedebergs Arch Pharmacol. 1989. PMID: 2475788 - Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.
Wang JC, Kiyosue T, Kiriyama K, Arita M. Wang JC, et al. Br J Pharmacol. 1999 Dec;128(8):1733-8. doi: 10.1038/sj.bjp.0702959. Br J Pharmacol. 1999. PMID: 10588929 Free PMC article. - Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties.
Osaka T, Kodama I, Toyama J, Yamada K. Osaka T, et al. Br J Pharmacol. 1988 Apr;93(4):775-80. doi: 10.1111/j.1476-5381.1988.tb11462.x. Br J Pharmacol. 1988. PMID: 3260528 Free PMC article. - Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
Hollingshead LM, Faulds D, Fitton A. Hollingshead LM, et al. Drugs. 1992 Nov;44(5):835-57. doi: 10.2165/00003495-199244050-00009. Drugs. 1992. PMID: 1280569 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources